甲氨蝶呤降低类风湿关节炎心血管风险:疾病活动度中介作用分析
本研究基于美国退伍军人类风湿关节炎前瞻性队列,采用边际结构模型分析甲氨蝶呤(MTX)使用与心血管疾病(CVD)风险的关联,并评估疾病活动度改变是否介导该效应。结果显示MTX使用与复合CVD事件风险降低24%相关,其中心衰住院风险降低57%,但中介分析未发现疾病活动度改变的中介效应。
要点
- MTX使用与复合CVD事件风险降低24%相关(HR 0.76,95%CI 0.58-0.99)。
- MTX使用与心衰住院风险降低57%相关(HR 0.43,95%CI 0.24-0.77)。
- 疾病活动度改变未介导MTX对CVD风险的影响(HR 1.03,95%CI 0.80-1.32)。
核心结论
- 在RA患者中,MTX使用与CVD事件风险降低相关,尤其与心衰住院风险降低相关。
- MTX对CVD风险的降低作用并非通过降低RA疾病活动度介导,提示其他机制可能参与。
研究设计与样本
- 多中心前瞻性队列研究,纳入2044例美国退伍军人RA患者(90%男性,平均年龄63.9岁,基线DAS28-CRP 3.6)。
- 采用边际结构模型(MSM)估计MTX对CVD事件的治疗效应,并校正时间依赖性混杂因素。
- 进行中介分析,评估MTX通过改变RA疾病活动度对CVD风险的间接效应。
主要发现
- 随访期间共发生378例新发CVD事件。
- MTX使用与复合CVD事件风险降低24%相关(HR 0.76,95%CI 0.58-0.99)。
- MTX使用与心衰住院风险降低57%相关(HR 0.43,95%CI 0.24-0.77)。
- MTX与冠心病、卒中和CVD死亡的关联无统计学意义。
- 中介分析未发现疾病活动度改变介导MTX对CVD风险的影响(HR 1.03,95%CI 0.80-1.32)。
临床怎么用
- 在RA患者中,使用MTX可能与降低CVD风险(尤其心衰住院)相关,支持其心血管获益。
- MTX的心血管保护作用不完全依赖于疾病活动度控制,临床决策时需综合考虑。
局限性
- 研究人群以男性退伍军人为主(90%),结果外推需谨慎。
- 观察性设计可能存在残余混杂。
- 中介分析未发现疾病活动度的中介效应,但可能存在未测量的中介因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Examine the association of methotrexate (MTX) use with cardiovascular disease (CVD) in rheumatoid arthritis (RA) using marginal structural models (MSM) and determine if CVD risk is mediated through modification of disease activity. METHODS: We identified incident CVD events (coronary artery disease (CAD), stroke, heart failure (HF) hospitalisation, CVD death) within a multicentre, prospective cohort of US Veterans with RA. A 28-joint Disease Activity Score with C-reactive protein (DAS28-CRP) was collected at regular visits and medication exposures were determined by linking to pharmacy dispensing data. MSMs were used to estimate the treatment effect of MTX on risk of incident CVD, accounting for time-varying confounders between receiving MTX and CVD events. A mediation analysis was performed to estimate the indirect effects of methotrexate on CVD risk through modification of RA disease activity. RESULTS: Among 2044 RA patients (90% male, mean age 63.9 years, baseline DAS28-CRP 3.6), there were 378 incident CVD events. Using MSM, MTX use was associated with a 24% reduced risk of composite CVD events (HR 0.76, 95% CI 0.58 to 0.99) including a 57% reduction in HF hospitalisations (HR 0.43, 95% CI 0.24 to 0.77). Individual associations with CAD, stroke and CVD death were not statistically significant. In mediation analyses, there was no evidence of indirect effects of MTX on CVD risk through disease activity modification (HR 1.03, 95% CI 0.80 to 1.32). CONCLUSIONS: MTX use in RA was associated with a reduced risk of CVD events, particularly HF-related hospitalisations. These associations were not mediated through reductions in RA disease activity, suggesting alternative MTX-related mechanisms may modify CVD risk in this population.
引用
- Johnson TM, Sayles HR, Baker JF, et al. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis. Ann Rheum Dis. 2021. PMID: 34049859. doi:10.1136/annrheumdis-2021-220125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。